Anavex Life Sciences Corp (AVXL)

[Anshu2]

AD trial was completed July 2022. After 1.5 years what data do we have:

1. 12.22. Botched/incomplete data. Claiming full success based on likely-changed-at-last-minute measures (OR) — that too full of many errors.

2. 2H23: Changed the measures to LMS. Excluded one endpoint (ADL). Some grossly incomplete data on a couple of biomarkers.

NOTHING ELSE! That can only mean one thing — the missing pieces of data are negative. 100%.

Of course — the blinded ones consider the trial to be a success — and even hoping for FDA approval! FDA will never approve based on current trials (even though I haven’t seen all the data). EU may.